Horizon數位前沿主動型ETF YNOT 深 滬
等待開盤 06-25 09:30:00 美东时间
31.76
-0.268
-0.84%
華盛通- 最 高32.22
- 今 開32.04
- 成交量 5356股
- 最 低 31.76
- 昨 收 32.0283
- 總市值 1.18亿
- 52周最高 35.02
- 市盈率 靜 --
- 換手率 0.14%
- 52周最低 25.08
- 委 比 -49.46%
- 總股本 373.00万
- 歷史最高 35.02
- 量 比 0.90
- 振 幅 1.44%
- 歷史最低 25.08
- 每 手 1
- 風險率 2.14%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Moderna snaps after six-session winning streak
Moderna (MRNA) snapped a six-session winning streak on Monday, with shares falling 6.10% to $60.06 in afternoon trading. Despite the decline, the stock has been one of the market's standout performers...
06-23 02:05
Moderna gains unanimous FDA panel endorsement of flu vaccine
A US FDA advisory panel unanimously agreed that the benefits of Moderna's (MRNA) mRNA seasonal flu vaccine, mRNA-1010, outweigh the risks in individuals 50-75 years old. The agency's Vaccines and Rela...
06-19 05:00
Moderna eyes German production sites amid BioNTech plant closures - report
U.S. vaccine maker Moderna (MRNA) is exploring investments in manufacturing facilities in Germany and is particularly interested in acquiring sites that rival BioNTech (BNTX) plans to shut down as par...
06-17 15:19
Moderna hires commercial chief ahead of multiple product launches
Moderna (MRNA) on Tuesday said that Ester Banque, a former senior executive at Zoetis (ZTS) and Bristol Myers (BMY), will join the company as chief commercial officer as part of organizational changes...
06-16 20:57
默沙东(MRK)股票6月15日盘中下跌3.13%：真相来了
• CMS拟议的药品价格谈判影响了默克未来的营收。 • 肿瘤学试验中的研发管线受挫，引发了市场对增长前景的担忧。 • 除息日因素也导致了股价的下跌。
06-15 18:16
Merck And Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Trial After Trodelvy–KEYTRUDA Combination Fails To Achieve Statistically Significant Progression-Free Survival Benefit In First-Line Metastatic NSCLC
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (NASDAQ:GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead's
06-09 04:31
Moderna, Merck release promising data on mRNA cancer vaccine
Moderna (MRNA) and Merck (MRK) said that the experimental cancer vaccine intismeran autogene plus Keytruda (pembrolizumab) led to a 49% decline in the risk of recurrence or death, and a 50% reduction ...
06-02 04:53
Tempus AI Announces Latest Results From Its Mission To Build Multimodal Foundation Models At The 2026 American Society Of Clinical Oncology Annual Meeting
Tempus has been building novel biological foundation models and agentic workflows by leveraging its more than 500 petabytes of rich, molecularly grounded data—more than 45 million total de-identified patient journeys,
05-29 21:17
Merck wins EU CHMP backing for Keytruda-Padcev in cisplatin-ineligible bladder cancer
Merck wins EU CHMP backing for Keytruda-Padcev in cisplatin-ineligible bladder cancer EU drug regulators issued a positive CHMP opinion for Keytruda with Padcev as perioperative therapy for cisplatin-ineligible adults with resectable muscle-invasive bladder cancer. The European Commission is reviewi
05-22 19:55
Merck Announces New Research From 100+ Abstracts Across 25+ Types Of Cancer From Its Oncology Portfolio And Pipeline To Be Presented At The 2026 American Society Of Clinical Oncology Annual Meeting, May 29-June 2
Five-year follow-up data from KEYNOTE-942 underscore the continued potential of intismeran autogene (mRNA-4157 or V940) in combination with KEYTRUDA® (pembrolizumab) for patients with resected high-risk
05-12 18:49
